Dorzolamide Hydrochloride + Timolol MaleateThird Party Manufacturing in India

Dorzolamide Hydrochloride + Timolol Maleate works by lowering elevated intraocular pressure via dual aqueous humor pathways. Dorzolamide inhibits carbonic anhydrase II to lower bicarbonate ion secretion in the ciliary processes, while Timolol blocks beta-adrenergic receptors to directly reduce fluid production. It inhibits excessive fluid accumulation to help the body protect the optic nerve from pressure damage. Unlike single anti-glaucoma drugs, it yields a greater compound drop in ocular pressure. It is highly effective and well-tolerated.

Therapeutic Uses

• Open-Angle Glaucoma: Controls intraocular pressure in patients who are inadequately responsive to standalone beta-blockers.
• Ocular Hypertension: Lowers elevated pressure profiles to prevent permanent visual field deterioration.
• Optic Nerve Protection: Maintains healthy aqueous fluid dynamics to shield nerve pathways from chronic physical stress.

Why Manufacturers Choose Dorzolamide Hydrochloride + Timolol Maleate

This formulation represents an essential, high-volume chronic therapy item within the global glaucoma segment. Choosing Dorzolamide Hydrochloride + Timolol Maleate third party manufacturing in India allows your marketing company to address long-term patient prescription cycles. Our partner facilities hold WHO-GMP certification, providing expert-level chemical buffering systems to ensure long-term stability and precise active dosing across variable strengths.